Evidence map›Paper›PMID 29262838›Full record

ArticleSubstance abuse treatment, prevention, and policy2017

Quality measurers of therapeutic communities for substance dependence: an international collaborative study survey in Latin America.

Carlos Gómez-Restrepo, Patricia Maldonado, Nelcy Rodríguez, Rafael Ruiz-Gaviria, Miguel Ángel Escalante, Raúl Ángel Gómez, Marcelo Ribeiro de Araujo, Ana Carolina Schmidt de Oliveira, Joel Salvador Chávez Rivera, Jorge Alberto Godínez García and 2 more

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Carlos Gómez-RestrepoDepartment of Clinical Epidemiology and Biostatistics, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia. cgomez_restrepo@yahoo.com.ORCID 0000-0002-9013-5384
Patricia MaldonadoSchool of Medicine, Pontificia Universidad Javeriana, Bogota, Colombia.
Nelcy RodríguezDepartment of Clinical Epidemiology and Biostatistics, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia.
Rafael Ruiz-GaviriaDepartment of Clinical Epidemiology and Biostatistics, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia.
Miguel Ángel EscalanteUnity of Epidemiological Studies in Mental Health, Psychology Faculty, National University of Cordoba, Cordoba, Argentina.
Raúl Ángel GómezUnity of Epidemiological Studies in Mental Health, Psychology Faculty, National University of Cordoba, Cordoba, Argentina.
Marcelo Ribeiro de AraujoDepartment of Psychiatry, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Ana Carolina Schmidt de OliveiraDepartment of Psychiatry, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Joel Salvador Chávez RiveraConsejero Terapéutico State Council Against Addictions, Guadalajara, Jalisco, Mexico.
Jorge Alberto Godínez GarcíaPolymetrix, Cabo San Lucas, Jalisco, Mexico.
Marina Piazza FerrandUniversidad Peruana Cayetano Heredia, Lima, Perú.
Dora Blitchtein-WinickiNational Institute of Public Health, Lima, Peru.
Pontificia Universidad Javeriana · COUniversidade Federal de São Paulo · BRUniversidad Nacional de Córdoba · ARHospital Civil de Guadalajara · MXNational Institute of Quality · PESecretaría de Salud de Jalisco · MXUniversidad Peruana Cayetano Heredia · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Latin America, substance related disorders are highly prevalent and one of the treatment strategies is the Therapeutic Communities (TCs), however, in Latin America there is scarce data about this treatment strategies, their quality, drop-out rates and patient satisfaction.

methodsBased on a previous study in 5 Latin American countries, the TCs who had a score equal or higher than 9 according to the De Leon criteria which are some fundamental items that the TCs should meet, were selected to carry out a descriptive and retrospective study of qualitative and quantitative characteristics of the TCs.

resultsData from 58 TCs in 5 countries were included, with a sample of 1414 patients interviewed, of which most were single men, with no hospitalization history in a therapeutic community. Marijuana was the most commonly substance used in the 30 days prior to hospitalization, with 78% of interviewees referring alcohol consumption in the last 6 months and an average onset of psychoactive substances at 16 years of age. A 79% of the patients interviewed perceived some improvement during their stay in the TCs. The less fulfilled Quality Indicators by the TCs were "Requesting a professional qualification to former addicts that belonged to the program" and "Work as part of the therapeutic program". Among the reasons for discharge found in the database, 44% were due to therapeutic discharge with fulfillment of the treatment plan and 44% withdraws.

conclusionThe user satisfaction with TCs, in terms of infrastructure and quality are quite high, as the fulfillment of essential quality items, however, the follow up information to evaluate effectiveness of the treatment is poor or in some cases unknown.

Indexed as

InternationalityTherapeutic CommunityFemaleHumansLatin AmericaMaleOutcome Assessment, Health CarePatient DropoutsPatient SatisfactionRetrospective StudiesSubstance-Related DisordersSurveys and QuestionnairesPatient compliancePatient satisfactionSubstance-related disordersTherapeutic communities (TCs)

Identifiers

PMID29262838
PMCPMC5738167
OpenAlexW2776635928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.